Article Text

Download PDFPDF

Original article
Effect of fissure integrity on lung volume reduction using a polymer sealant* in advanced emphysema
Free
  1. Helgo Magnussen1,
  2. Mordechai R Kramer2,
  3. Anne-Marie Kirsten1,
  4. Charles Marquette3,
  5. Arschang Valipour4,
  6. Franz Stanzel5,
  7. Reiner Bonnet6,
  8. Juergen Behr7,
  9. Oren Fruchter2,
  10. Yael Refaely8,
  11. Ralf Eberhardt9,
  12. Felix J F Herth9
  1. 1Pulmonary Research Institute at Hospital Groβhansdorf, Center for Pneumology and Thoracic Surgery, Groβhansdorf, Germany
  2. 2Rabin Medical Center, Beilinson Hospital, Petah Tikva, Tel Aviv, Israel
  3. 3Service de Pneumologie Hôpital Pasteur-Pavillon H, Centre Hospitalier Universitaire, Nice, France
  4. 4Department of Respiratory and Critical Care Medicine, Ludwig Boltzmann Institute for COPD, Otto Wagner Hospital, Vienna, Austria
  5. 5Lungenklinik Hemer, Pneumologie—Thorakale Endoskopie, Hemer, Germany
  6. 6Zentralklinik Bad Berka GmbH, Klinik für Pneumologie, Bad Berka, Germany
  7. 7Universitätsklinikum Bergmannsheil GmbH, Medizinische Klinik III für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Bochum, Germany
  8. 8Division of Thoracic Surgery, Saroka Medical Center, Be'er Sheva, Israel
  9. 9Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany
  1. Correspondence to Professor Helgo Magnussen, Pulmonary Research Institute at Hospital Groβhansdorf, Center for Pneumology and Thoracic Surgery, Groβhansdorf, Groβhansdorf 22927, Germany; magnussen{at}pulmoresearch.de

Abstract

Rationale Interlobar fissure integrity has previously correlated with responsiveness to endobronchial lung volume reduction therapy in patients with advanced emphysema.

Objective This report summarises the effect of interlobar fissure integrity on responses to treatment with a novel endoscopic tissue sealant (AeriSeal emphysematous lung sealant (ELS)) that collapses hyperinflated lung.

Methods Fissure status, lung volumes, tissue density and disease heterogeneity were assessed radiographically in 28 patients (age 63.4±6.1 years, 20 men) with advanced upper lobe predominant emphysema (density=888.0±18.2 HU; upper lobe tissue density <−950=2.62±1.74). Post-treatment changes in lobar volume, pulmonary function, exercise capacity, symptoms and quality of life were compared in patients with complete fissures (CFs) and incomplete fissures (ICFs).

Results ELS therapy reduced lung volumes independent of interlobar fissure integrity. In patients with upper lobe emphysema and CFs, lobar volume reduction was 214±127 ml/treatment compared with 256±175 ml/treatment in those with ICFs (p=0.453). Reductions in gas trapping and improvements in spirometry, functional capacity and quality of life were similar in patients with CFs and ICFs. Stepwise multiple regression modelling confirmed that fissure integrity did not contribute to post-treatment changes in forced expiratory volume in 1 s, residual volume/total lung capacity ratio or lobar volume measured by CT analysis.

Conclusions Interlobar fissure integrity, an important determinant of responsiveness to endobronchial lung volume reduction therapy in prior studies, had minimal impact on physiological and functional responses to ELS therapy in patients with severe upper lobe predominant emphysema.

Clinical trial registration number Registration numbers for trials contributing to datasets in this report: NCT00884962, NCT01051258 and NCT01181466.

  • Bronchoscopic lung volume reduction
  • emphysema therapy
  • interventional pulmonology
  • CT scanning
  • COPD mechanisms
  • asthma
  • asthma pharmacology
  • COPD pharmacology
  • exhaled airway markers
  • long-term oxygen therapy (LTOT)
  • lung physiology
  • pulmonary rehabilitation
  • bronchoscopy
  • COPD exacerbations
  • emphysema
  • massive haemoptysis
  • sleep apnoea
  • histology/cytology
  • interstitial fibrosis
  • lung cancer
  • lung cancer chemotherapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • See Editorial, p 285

  • Funding Support for this study was provided by Aeris Therapeutics, Woburn, Massachusetts, USA.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Freiberg Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles